Biogen, Samsung Bioepis and Abbvie settle patent dispute
Biogen and Samsung Bioepis have laid to rest a long-running patent wrangle with AbbVie regarding a biosimilar form of the latter’s blockbuster Humira.
The parties have now come to an agreement over the commercialisation of Biogen and Samsung Bioepis’ Imraldi (biosimilar adalimumab), the specific terms of which are being kept under wraps.
It was disclosed, however, that under the settlement AbbVie will grant patent licenses for the use and sale of Imraldi in Europe, on a country-by-country basis, while Biogen and Samsung Bioepis will make royalty payments in return.
Read more: http://www.pharmatimes.com/news/biogen,_samsung_bioepis_and_abbvie_settle_patent_dispute_1230636
The parties have now come to an agreement over the commercialisation of Biogen and Samsung Bioepis’ Imraldi (biosimilar adalimumab), the specific terms of which are being kept under wraps.
It was disclosed, however, that under the settlement AbbVie will grant patent licenses for the use and sale of Imraldi in Europe, on a country-by-country basis, while Biogen and Samsung Bioepis will make royalty payments in return.
Read more: http://www.pharmatimes.com/news/biogen,_samsung_bioepis_and_abbvie_settle_patent_dispute_1230636